Founded in 1963, bioMérieux has always been committed to developing in vitro diagnostic products for medical and industrial purposes, relying on its own scientific research and industrial production resources. The group specializes in designing, developing, producing, and promoting systems for clinical and industrial applications. bioMérieux's diagnostic systems consist of reagents, instruments, and software, primarily designed for four strategic areas: ***, industrial microbial control, cardiovascular diseases, and oncological diseases. In 2009, the company achieved sales of EUR 1,223 million. The group boasts a total of 17 production bases and 13 research centers, spread across Europe, North America, and South America. The group operates 39 subsidiaries worldwide, and as of December 31, 2009, employed over 6,500 people.